Azacitidine is indicated for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
Azacitidine
Specifications
Human
Injectable
Commercial
FEATURED Products
Related Media
New Product Development
Where our FDA approved laboratory begins developing products, formulating and validating methods to ensure quality.
Compliance Audits
Where we audit and champion our partner factories to exceed cGMP standards set by authorities.
Regulatory Services
Where all submissions are filed with the knowledge and experience of our 550+ worldwide approvals on record.